Primary source: OECD/EU report, Health at a glance: Europe 2024
MAHs and sponsors can expect enhanced requirements for pregnancy-specific safety signals and new methodological guidance for safety studies in pregnant populations.
These initiatives will likely improve drug safety assessments for women, particularly regarding pregnancy and breastfeeding, ensuring better health outcomes for this demographic.
Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Initiatives include detailed analyses of CTIS data for women's representation, improving methods for pregnancy-specific safety signal detection, developing pregnancy pharmacoepidemiologic methodological guidance, and strengthening pharmacovigilance practices with specific guidelines for pregnancy and breastfeeding.
MAHs and sponsors can expect enhanced requirements for pregnancy-specific safety signals, new methodological guidance for safety studies in pregnant populations, and updated PV practices for monitoring safety in women.
Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
The European Medicines Agency is enhancing its focus on women's health in medicine by launching initiatives aimed at improving clinical trial representation, developing pregnancy-specific safety assessment methods, and strengthening pharmacovigilance guidelines.
What changed: MAHs and sponsors can expect enhanced requirements for pregnancy-specific safety signals and new methodological guidance for safety studies in pregnant populations.
Why it matters: These initiatives will likely improve drug safety assessments for women, particularly regarding pregnancy and breastfeeding, ensuring better health outcomes for this demographic.
Practical implication: Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
